Back to discover
Disease

Raynaud's Disease

Late-stage therapeutic developmentEmerging research
MeSHRaynaud Disease
1
Publications
8
Clinical trials
2017
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Research2016-11-09Annals of the rheumatic diseases

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
0
Active
4
Late-stage
6
Completed
Recently completed

Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

N/A · Completed · University Hospital, Grenoble

Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)

Phase 2 · Completed · Bayer

Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma

Phase 3 · Completed · Sanjay Gandhi Postgraduate Institute of Medical Sciences

Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon

Phase 2 · Completed · VSM Geneesmiddelen b.v.

Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon

Phase 2/3 · Completed · MediQuest Therapeutics

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

Phase 3 · Completed · National Center for Research Resources (NCRR)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Update of EULAR recommendations for the treatment of systemic sclerosis.

Annals of the rheumatic diseases · 2017 · 708 cites
Recent publications

Update of EULAR recommendations for the treatment of systemic sclerosis.

Annals of the rheumatic diseases · 2017 · 708 cites
Leading journals1
  • Annals of the rheumatic diseases1
Leading researchers8
  • Allanore Y1
  • Avouac J1
  • Becker M1
  • Clements P1
  • Cutolo M1
  • Czirjak L1
  • Damjanov N1
  • Del Galdo F1
Affiliations (unnormalised)6
  • Basel University1
  • Central Manchester NHS Foundation Trust1
  • Cochin Hospital1
  • Department of Rheumatology and Clinical Immunology1
  • Ghent University Hospital1
  • Hamburg Centre for Pediatric and Adolescence Rheumatology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.

Identifiers
MeSHRaynaud Disease
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.